• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

作者信息

Bosanquet Nick, Yeates Andrew

出版信息

Pharmacoeconomics. 2006;24(6):623-5; author reply 625-6. doi: 10.2165/00019053-200624060-00008.

DOI:10.2165/00019053-200624060-00008
PMID:16761908
Abstract
摘要

相似文献

1
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.模拟胆碱酯酶抑制剂在轻度至中度重度阿尔茨海默病管理中的成本效益。
Pharmacoeconomics. 2006;24(6):623-5; author reply 625-6. doi: 10.2165/00019053-200624060-00008.
2
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.模拟胆碱酯酶抑制剂在轻度至中度重度阿尔茨海默病管理中的成本效益。
Pharmacoeconomics. 2005;23(12):1271-82. doi: 10.2165/00019053-200523120-00010.
3
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.痴呆胆碱酯酶抑制剂治疗的经济学评价：阿尔茨海默病与路易体痴呆的比较。
Int J Geriatr Psychiatry. 2009 Oct;24(10):1072-8. doi: 10.1002/gps.2223.
4
The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.英国针对不同严重程度的阿尔茨海默病进行次优治疗所产生的成本效益影响。
Int J Geriatr Psychiatry. 2018 Feb;33(2):307-315. doi: 10.1002/gps.4745. Epub 2017 Jun 14.
5
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.胆碱酯酶抑制剂治疗阿尔茨海默病的成本效益：一项包含方法学考量的综述
Drugs Aging. 2004;21(5):279-95. doi: 10.2165/00002512-200421050-00001.
6
NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?英国国家卫生与临床优化研究所对胆碱酯酶抑制剂的成本效益评估：提出的问题正确吗？使用的是最佳工具吗？
Pharmacoeconomics. 2007;25(12):997-1006. doi: 10.2165/00019053-200725120-00003.
7
Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.治疗阿尔茨海默病（AD）的胆碱酯酶抑制剂的药物经济学。
Acta Neurol Belg. 2012 Jun;112(2):141-5. doi: 10.1007/s13760-012-0062-9. Epub 2012 Apr 4.
8
The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?阿尔茨海默病试验的后现代世界：在伦敦市中心，一个阿尔茨海默病评估量表认知部分（ADAS-cog）得分价值几何？
Int J Geriatr Psychiatry. 2006 Jan;21(1):9-13. doi: 10.1002/gps.1492.
9
Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.阿尔茨海默病乙酰胆碱酯酶抑制剂和美金刚有效性和成本效益的证据演变：系统评价和经济模型。
Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22.
10
The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
J Am Med Dir Assoc. 2004 Jul-Aug;5(4):249-55. doi: 10.1097/01.JAM.0000131500.41375.1D.

引用本文的文献

1
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.使用离散事件模拟评估多奈哌齐在德国治疗阿尔茨海默病的成本效益。
BMC Neurol. 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2.
2
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.多奈哌齐治疗轻中度阿尔茨海默病的成本效果评价：英国应用离散事件模拟的研究
Pharmacoeconomics. 2010;28(5):411-27. doi: 10.2165/11531870-000000000-00000.
3
NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

本文引用的文献

1
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.模拟胆碱酯酶抑制剂在轻度至中度重度阿尔茨海默病管理中的成本效益。
Pharmacoeconomics. 2005;23(12):1271-82. doi: 10.2165/00019053-200523120-00010.
2
Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.阿尔茨海默病中的健康效用及其对成本效益分析的影响。
Pharmacoeconomics. 2005;23(6):537-41. doi: 10.2165/00019053-200523060-00002.
3
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
英国国家卫生与临床优化研究所对胆碱酯酶抑制剂的成本效益评估：提出的问题正确吗？使用的是最佳工具吗？
Pharmacoeconomics. 2007;25(12):997-1006. doi: 10.2165/00019053-200725120-00003.
4
Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations.胆碱酯酶抑制剂在痴呆症护理中的作用：英国国家卫生与临床优化研究所的经济分析存在局限性。
BMJ. 2006 Sep 16;333(7568):603. doi: 10.1136/bmj.333.7568.603.
多奈哌齐治疗阿尔茨海默病神经精神症状的疗效。
Neurology. 2004 Jul 27;63(2):214-9. doi: 10.1212/01.wnl.0000129990.32253.7b.
4
Does diagnosis determine delivery? The Islington study of older people's needs and health care costs.诊断决定分娩方式吗？伊斯灵顿老年人需求与医疗保健成本研究。
Psychol Med. 2004 Jan;34(1):147-55. doi: 10.1017/s0033291703008808.
5
Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.多奈哌齐与阿尔茨海默病患者延迟入住养老院有关。
J Am Geriatr Soc. 2003 Jul;51(7):937-44. doi: 10.1046/j.1365-2389.2003.51306.x.
6
Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.多奈哌齐对中度阿尔茨海默病患者的功能、认知及行为影响
Curr Med Res Opin. 2002;18(6):347-54. doi: 10.1185/030079902125001029.
7
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.胆碱酯酶抑制剂治疗改变阿尔茨海默病的自然病程。
J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):310-4. doi: 10.1136/jnnp.72.3.310.
8
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.一项为期1年、以安慰剂为对照的多奈哌齐对阿尔茨海默病患者功能保留生存期的研究。
Neurology. 2001 Aug 14;57(3):481-8. doi: 10.1212/wnl.57.3.481.
9
Cognitive disability and direct care costs for elderly people.老年人的认知障碍与直接护理成本
Br J Psychiatry. 1999 Jun;174:539-46. doi: 10.1192/bjp.174.6.539.
10
Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII.阿尔茨海默病患者机构化时间的预测因素：CERAD研究经验，第十七部分。
Neurology. 1997 May;48(5):1304-9. doi: 10.1212/wnl.48.5.1304.